News | Prostate Cancer | December 14, 2016

Cancer Targeted Technology Commences Phase I Clinical Trial of Prostate Cancer Imaging Agent

Trial will evaluate safety and tolerability of PET agent that binds to PSMA with enhanced uptake and internalization

December 14, 2016 — Cancer Targeted Technology (CTT), a privately-held Seattle-based biotechnology firm focusing on small molecules that target pivotal enzyme targets on cancer, announced a Phase I clinical trial has commenced in men with high-risk metastatic prostate cancer. In late August, the U.S. Food and Drug Administration cleared CTT’s first Investigational New Drug Application (IND) for a positron emission tomography (PET) imaging agent, CTT1057, labeled with a two-hour half life radiolabel, fluorine-18, and targeting prostate-specific membrane antigen (PSMA).

PSMA is over-expressed on prostate cancer and this expression increases as the cancer metastasizes and becomes castrate-resistant. CTT’s phosphoramidate-based agents bind irreversibly to PSMA and unlike other agents targeting PSMA, this distinctive mode of binding enhances uptake and internalization by tumor cells, leading to increased accumulation of the drug and radiolabel within the tumor. The first patient in this trial was imaged in early November and the study is supported by a $2M Small Business Innovation Research (SBIR) grant.

In the trial, CTT1057 will either be used alone or with CTT’s companion radiotherapeutic drug, CTT1403, that targets metastatic prostate cancer, according to CTT CEO and SBIR principal investigator Beatrice Langston-Webster. CTT1403 is currently undergoing IND-enabling studies.”

Automated radiolabeling of the drug and the clinical trials are being conducted at the University of California, San Francisco (UCSF). The principal investigator for the clinical trial is Rahul Aggarwal, M.D. The radiolabeling is directed by UCSF collaborator Henry VanBrocklin, Ph.D., director of the Radiopharmaceutical Research Program, who worked with CTT on the initial development of CTT1057, along with Cliff Berkman, Ph.D., professor of chemistry at Washington State University, who first discovered and synthesized the drug.

VanBrocklin commented, “We are excited to initiate the clinical phase of development of this new imaging agent and look forward to the results of these key studies.”

This CTT-sponsored Phase I trial is entitled “A Phase 1 Trial for Evaluation of the Safety, Pharmacokinetics, and [18F] Radiation Dosimetry of CTT1057, a Small Molecule Inhibitor of Prostate Specific Membrane Antigen (PSMA).” The primary objective of this trial is to evaluate the safety and tolerability of CTT1057. An additional endpoint includes the assessment of sensitivity and specificity of CTT1057 PET imaging on a lesion-by-lesion basis as compared with standard imaging in metastatic prostate cancer. Twenty patients will be enrolled in parallel in two cohorts: Cohort A will enroll patients with prostate cancer prior to radical prostatectomy (N = 5) and Cohort B will enroll patients with evidence of metastatic castration-resistant prostate cancer (N = 15). The study is currently enrolling and is expected to conclude in mid 2017.

For more information: www.cancertargetedtechnology.com

Related Content

Prenatal MRI of a Zika fetus showing enlarged cerebral fluid space, dilation of the cerebral ventricles, thinning of brain tissue, poorly developed cerebellum and the absence of brain cortical gyri. (Image coutesy of RSNA)

Feature | Women's Health | January 23, 2017 | Dave Fornell
The rapid spread of Zika virus in the Western Hemisphere this past year has caused great alarm in the United States,
breast cancer screening, substantial overdiagnosis, Annals of Internal Medicine study
News | Mammography | January 19, 2017
Breast cancer screening in Denmark was associated with a substantial increase in the incidence of nonadvanced tumors...
automated volumetric breast density, Elizabeth Wende Breast Care, EWBC, American Journal of Roentgenology, mammographic sensitivity
News | Breast Density | January 18, 2017
Researchers from Elizabeth Wende Breast Care (EWBC) have demonstrated that automated volumetric breast density has a...
prostate cancer, PI-RADS, best clinical research paper, European Urology
News | Prostate Cancer | January 18, 2017
An article promoting standardized imaging efforts to improve diagnosis and treatment of prostate cancer has been...
stress, brain activity, cardiovascular risk, PET-CT, MGH, ISSMS, The Lancet study
News | Neuro Imaging | January 18, 2017
A study led by Massachusetts General Hospital (MGH) and Icahn School of Medicine at Mount Sinai (ISSMS) investigators...
News | Radiopharmaceuticals and Tracers | January 17, 2017
NorthStar Medical Technologies LLC has received additional matching funds from the U.S. Department of Energy’s National...
metastatic colorectal cancer, mCRC, Sirtex, NCCN guidelines, Y-90 microspheres
News | Radiation Therapy | January 03, 2017
Sirtex Medical Limited announced in December that SIR-Spheres Y-90 resin microspheres have been included as a Category...
Elder abuse, radiologists can detect elder abuse, medical imaging
News | Imaging | January 02, 2017
January 2, 2017 — Radiologists may be uniquely positioned to identify elder abuse, but they do not have training or e
pregnancy brain, pregnant brain, pregnancy's effect on the brain

An image from the study showing brain volume changes in women post pregnancy. Image by Oscar Vilarroya.

 

 

News | Magnetic Resonance Imaging (MRI) | December 28, 2016
December 28, 2016 — Pregnancy involves radical hormone surges and biological adaptations, but the effects on the brai
SNMMI Develops USP Recommendations for Compounded Sterile Radiopharmaceuticals
News | December 28, 2016
December 28, 2016 — The Society of Nuclear Medicine and Molecular Imaging (SNMMI) has developed United States Pharmac
Overlay Init